

MODERN SLAVERY & HUMAN TRAFFICKING STATEMENT

Inomed Health Limited

2026 STATEMENT | FY2025/26 | APPROVAL DATE 9 AUGUST 2026

Document field	Details
Supplier	Inomed Health Limited
Statement status	Voluntary modern slavery transparency statement
Financial year covered	1 April 2025 to 31 March 2026
Primary activity	Distribution of advanced medical devices and clinical support
Approval authority	Director - Shazad Ali
Public publication date	10 August 2026 - planned public release via unrestricted read-only SharePoint link while the corporate website is temporarily unavailable.
Review frequency	At least annually and when material supply-chain risks change

PUBLIC SUPPLIER DOCUMENT • ENTERPRISE GOVERNANCE & PROCUREMENT SUPPORTING EVIDENCE

Our commitment

Inomed Health Limited is committed to conducting business ethically, respecting human rights and taking proportionate steps to identify, prevent and address the risk of modern slavery and human trafficking in our operations and supply chain.

This statement is published voluntarily. It reflects the principles of section 54 of the Modern Slavery Act 2015 and the expectations placed on responsible suppliers working with the NHS and wider healthcare sector. It is intended to provide a transparent account of our current approach and the improvements we are continuing to make. This 2026 statement covers the financial year from 1 April 2025 to 31 March 2026.

Organisation and supply chain

Inomed Health Limited is a UK medical-technology supplier. Our primary activity is the distribution of advanced medical devices and the provision of clinical support. Our supply chain therefore includes medical-device manufacturers, logistics and freight providers, professional service providers and other suppliers that support the delivery of products and services to healthcare customers.

As a relatively small organisation, we apply a proportionate risk-based approach. We place particular focus on the upstream manufacture and movement of medical devices, outsourced services, labour practices in higher-risk geographies and the quality of information available from our direct suppliers.

Risk identification and due diligence

Modern slavery risk is considered during pre-procurement and specification activity and is incorporated into our supplier due-diligence approach. Our current controls include:

- desktop due-diligence reviews of Tier 1 suppliers and review of relevant corporate, quality and regulatory information;
- use of contractual expectations and supplier controls to reinforce ethical conduct and legal compliance;
- dialogue with suppliers where information gaps, higher-risk locations or other concerns are identified;
- monitoring and follow-up where corrective action or further evidence is required; and
- escalation and grievance routes so concerns can be raised and considered by management.

Supply-chain mapping

Full end-to-end supply-chain mapping is not yet complete. This remains an identified improvement area. We are progressively strengthening our records of direct suppliers, manufacturing locations and material logistics routes so that modern slavery risk can be assessed more consistently and evidence can be retained in a controlled manner.

Modern Slavery Assessment Tool (MSAT)

Inomed Health uses the UK Government Modern Slavery Assessment Tool (MSAT) as a continuous-improvement framework. A historic 2024 MSAT score of 79 is retained only as prior-cycle evidence and is not being presented as the current tender result. For the current 2026 procurement cycle, Inomed Health is required to complete a new/current MSAT in SRS, acknowledge any improvement actions and share the assessment with NHS Supply Chain Coordination (D-U-N-S N0000456000). The new score and sharing evidence will then be entered in Evergreen Section 17 and retained with the tender evidence pack.

How concerns are managed

Any concern relating to forced labour, trafficking, exploitation, unsafe working conditions or other serious labour-rights issues is expected to be escalated promptly to Inomed Health management. Where a concern is substantiated or requires further investigation, we may seek additional evidence, require corrective action, suspend onboarding or purchasing activity, or take other proportionate steps consistent with patient safety, contractual obligations and applicable law.

2026/27 improvement priorities and MSAT actions

Priority	Action / control	Status
MSAT	Complete the new/current SRS MSAT, acknowledge improvement actions, share with NHS Supply Chain Coordination (D-U-N-S N0000456000), and retain score/sharing evidence.	Required before tender evidence is finalised
Supply-chain mapping	Expand mapping of Tier 1 suppliers, manufacturing locations and logistics routes.	In progress
Risk review	Document modern slavery risk considerations during supplier onboarding and material procurement decisions.	Ongoing
Annual transparency	Review and republish this statement at least annually and after material changes.	Committed

Governance & director approval

Senior management oversees modern-slavery risk and improvement actions. Shazad Ali, Director, is the approval authority for this statement and its publication.

Approved for publication by: Shazad Ali
Role: Director

Approval date: 9 August 2026 | Public release: 10 August 2026
Signature: _____

